A beta version of life: p110beta takes center stage.
Article Details
- CitationCopy to clipboard
Dbouk HA, Backer JM
A beta version of life: p110beta takes center stage.
Oncotarget. 2010 Dec;1(8):729-33.
- PubMed ID
- 21321382 [ View in PubMed]
- Abstract
The PI3K pathway is frequently activated in tumors, most commonly through p110alpha mutation or PTEN deletion. In contrast to p110alpha, p110beta is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110alpha. In this perspective, we summarize recent data concerning the regulation of p110beta, which shows that wild-type p110beta acts like an oncogenic mutant of p110alpha. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110beta regulation on GPCR-driven tumorigenesis.